However, Ozempic is represented to be one of the GLP-1 receptor agonist medicines that was primarily developed to treat type 2 diabetes but has been discussed lately as regards overweight reduction medicines
Consequently, this route of delivery misses the opportunity to interact with the majority of GLP-1 receptors in the intestine, so the vagal afferents mechanism of action is unlikely to make a large contribution to its biological activity
But for alternating protocols, understanding this transition is equally important
The main factors are quantity, product form, assay and impurity requirements, documentation package, GMP or site evidence, batch status, lead time, packaging, destination market, shipment route, Incoterm, payment terms and supplier availability